Abstract: The invention provides among other things a stable, sterile pharmaceutical formulation comprising lyophilized azithromycin and ethanol. The invention also provides a method of producing a stable, sterile pharmaceutical product comprising lyophilized azithromycin. The invention also provides a pharmaceutical dosage form comprising the pharmaceutical formulation, as well as a method of treating a disease in a patient comprising administering a solution of the pharmaceutical formulation to a patient.
Abstract: The invention provides among other things a stable, sterile pharmaceutical formulation comprising lyophilized azithromycin and ethanol. The invention also provides a method of producing a stable, sterile pharmaceutical product comprising lyophilized azithromycin. The invention also provides a pharmaceutical dosage form comprising the pharmaceutical formulation, as well as a method of treating a disease in a patient comprising administering a solution of the pharmaceutical formulation to a patient.
Abstract: The present invention relates to an improved injectable ready-to-use preparation of pamidronate salts, methods for its manufacture and uses of the solution of the invention in the manufacture of pharmaceutical compositions for the treatment of diseases selected from the group of tumour-induced hypercalcaemia, Paget's disease, osteoporosis, bone metastases, or breast cancer. The ready-to-use solution comprises a physiologically acceptable alkaline salt of pamidronate which is water soluble and a physiologically acceptable aqueous solvent having a concentration of between 0.1 and 100 mg/mL, wherein the solution is provided in a sealed non-reactive plastic container.
Abstract: The present invention provides a stable, sterile, pharmaceutical product that consists essentially of lyophilized ifosfamide and solutions thereof. The lyophilized ifosfamide of the present invention is suitable for pharmaceutical use, and can be stored in one or more aseptically sealed containers. The present invention further provides a method of producing lyophilized ifosfamide, which method includes freezing a sterile solution of ifosfamide and subjecting it to a primary drying stage. The primary drying stage includes applying a vacuum to remove solvent while raising the temperature to a primary drying temperature, to produce a first intermediate. The first intermediate is subjected to a secondary drying stage, which includes applying a vacuum to further remove solvent while raising the temperature to a secondary drying temperature, to produce the pharmaceutical product.